Medivir invites to a conference call on new clinical data and further studies with MIV-818
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) invites to a conference call on the supporting clinical data from the completed dose escalation section of the phase 1b study with MIV-818, presented today at the European Society for Medical Oncology (ESMO) congress. The conference call will be held today, September 16, at 15:00 CET, to update on the study and the plan for the MIV-818 program. Medivir's lead candidate drug MIV-818 has the potential to become a liver-targeted, orally administered drug that can help patients with liver cancer. In April, it was announced that the